Liraglutide Peptide and Weight: Understanding the Research
There have been a number of recent studies to further understand the effect that the peptide liraglutide has with regard to hormones, weight, and mechanisms in the body. It’s hard not to explain what happens to peptides in one’s system without going too deep into the weeds of science and biology; but, we’re here to help break down what information is available to get a better grasp of Liraglutide’s impact on the body.
The science
One group of compounds called glucagon-like peptide-1 receptor agonists (GLP-1 RAs) includes the peptide ligand Liraglutide. Studies suggest it may aid blood sugar homeostasis and is a manufactured variant of the naturally occurring hormone glucagon-like peptide-1 (GLP-1). With 31 amino acids, long-acting GLP-1 RA ligand Liraglutide is 97% similar to the hormone’s active version, GLP-1 (7-37). A spacer glutamic acid residue modifies its structure by adding palmitate to the amino acid lysine at position 26 of GLP-1 (7-37).
Research indicates that renal excretion may be delayed because the linked fatty acid moiety might promote binding to serum albumin. Because of this, the half-life is believed to be thirteen hours. In addition, at position 34 of GLP-1, arginine is substituted for lysine. Novo Nordisk, a Danish pharmaceutical firm, discovered Liraglutide in 1990.
Polycystic ovarian syndrome (PCOS), non-alcoholic fatty liver disease (NAFLD), and other obesity-related disorders are now the focus of Liraglutide’s study.
Read on for further information on Liraglutide’s definition, potential, specific mechanisms of action, and where to get research-grade Liraglutide online.
Liraglutide Peptide: What is it?
Research indicates that Liraglutide may activate GLP-1 receptors in several organs, including the brain, pancreas, stomach, and adipose tissue, to imitate its effect.
Carbs trigger the production of GLP-1 in the intestines. It is an incretin believed to stimulate the pancreas to secrete insulin, which helps control blood sugar levels. Research has indicated that it is released into the hypothalamus after being produced by neurons in the brainstem, suggesting it might also be considered a neuropeptide.
In the same way that GLP-1 may increase insulin production by activating pancreatic beta cells, Liraglutide is hypothesised to decrease glucagon secretion by activating the GLP-1R on alpha cells. Scientists speculate that this may make it an excellent tool for the context of blood sugar levels in type 2 diabetes research.
Investigations purport that Liraglutide may stimulate the gastrointestinal GLP-1R to reduce further postprandial glucose spikes, which may slow stomach emptying. Studies suggest a 23% decrease in stomach emptying speed within the first hour of Liraglutide compared to a placebo. The normal gastric emptying rate is believed to be restored within four hours.
Theoretically, Liraglutide may improve insulin sensitivity by decreasing blood triglyceride release via its interaction with the GLP-1R in adipose tissue.
Ligarglutide is believed to help suppress hunger and exert neuroprotective potential by activating the GLP-1R in the brain. One of the main reasons why Ligarglutide may be relevant in overweight or obese research is that it is theorised to suppress appetite.
Liraglutide Peptide Potential
Many studies have examined the possible research potential of Liraglutide. Here are the most recent studies that researchers have conducted to understand Liraglutide and its potential better.
Adipose tissue reduction: Findings imply that Liraglutide may be impactful in obesity and weight-related research. No matter the diabetes status, Liraglutide has been hypothesised to potentially induce substantial weight reduction in several studies. According to the biggest meta-analysis on long-term Liraglutide presentation, the peptide seems to induce an average of 4-6% weight reduction, which included 6,000+ research cases as of publishing.
A meta-analysis of 43 randomised studies was conducted to determine Liraglutide’s potential in the context of type 2 diabetes mellitus. According to the analysis, Liraglutide seemed to effectively lower glycated haemoglobin (HbA1c) levels by 0.9%- 2.2% during the first six months after starting presentation. The favourable impacts of Liraglutide presentation appeared to have lasted at least 12 months.
Possibly lessening the likelihood of developing problems from type 2 diabetes: NAFLD, cardiovascular disease, renal disease, and non-alcoholic fatty liver disease are considered to be among the most prevalent consequences of form 2 diabetes. Scientists speculate that both type 2 diabetes with MI/stroke complications and cases with established atherosclerotic cardiovascular disease without an MI/stroke may potentially be aided by Liraglutide’s potential to lower the risk of significant adverse cardiovascular events. In addition, Liraglutide has been hypothesised to improve renal function indicators such as serum creatinine, cystatin C, urine albumin-creatinine ratio, and other inflammatory markers, as suggested by a meta-analysis of 18 RCTs that included 1,580 type 2 diabetes research cases.
According to animal studies, Liraglutide seems to enhance insulin sensitivity and encourage fatty acid oxidation in insulin-sensitive organs via the AMPK-Sirt-1 cell signalling pathway. Additionally, Liraglutide has been theorised to reduce levels of circulating and hepatic cytokines and stimulate brown adipocyte development in skeletal muscle. Research reports it may also have anti-inflammatory potential. Liraglutide has suggested promise in improving insulin sensitivity in animal studies. However, more investigation is necessary to explore this hypothesis.
Liraglutide has been the subject of studies designed to assess its neuroprotective potential in mild to moderate Alzheimer’s by measuring its impact on cerebral glucose absorption, cognitive tests, cortical volume, and protection. After 12 months of presentation, 204 models of mild Alzheimer’s dementia were randomised to receive Liraglutide or a placebo. The results implied that the group given Liraglutide appeared to have enhanced cognitive function and greater cortical volume than the control group. More studies are needed to validate these results. However, this does suggest that Liraglutide may have neuroprotective qualities.
References
[i] Müller, T. D., Finan, B., Bloom, S. R., D’Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., Holst, J. J., Langhans, W., Meier, J. J., Nauck, M. A., Perez-Tilve, D., Pocai, A., Reimann, F., Sandoval, D. A., Schwartz, T. W., Seeley, R. J., … Tschöp, M. H. (2019). Glucagon-like peptide 1 (GLP-1). Molecular metabolism, 30, 72–130. https://doi.org/10.1016/j.molmet.2019.09.010 [ii] Knudsen L. B. (2019). Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity. ACS pharmacology & translational science, 2(6), 468–484. https://doi.org/10.1021/acsptsci.9b00048 [iii] Knudsen, L. B., & Lau, J. (2019). The Discovery and Development of Liraglutide and Semaglutide. Frontiers in endocrinology, 10, 155. https://doi.org/10.3389/fendo.2019.00155 [iv] Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2015). Liraglutide for Type 2 diabetes and obesity: a 2015 update. Expert review of cardiovascular therapy, 13(7), 753–767. https://doi.org/10.1586/14779072.2015.1054810 [v] Albaker, W., Al Sheikh, M., Albakr, A., Alkhafaji, D., Al Besher, E., & Al-Hariri, M. (2021). The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients. International journal of general medicine, 14, 8643–8650. https://doi.org/10.2147/IJGM.S336904 [vi] Diene, G., Angulo, M., Hale, P. M., Jepsen, C. H., Hofman, P. L., Hokken-Koelega, A., Ramesh, C., Turan, S., & Tauber, M. (2022). Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity. The Journal of clinical endocrinology and metabolism, 108(1), 4–12. https://doi.org/10.1210/clinem/dgac549 [vii] Cabou, C., & Burcelin, R. (2011). GLP-1, the gut-brain, and brain-periphery axes. The review of diabetic studies: RDS, 8(3), 418–431. https://doi.org/10.1900/RDS.2011.8.418 [viii] Xu, X., Chen, J., Hu, L., Liang, M., Wang, X., Feng, S., Shen, J., & Luan, X. (2018). Liraglutide regulates the viability of pancreatic α-cells and pancreatic β-cells through cAMP-PKA signal pathway. Life sciences, 195, 87–94. https://doi.org/10.1016/j.lfs.2017.12.012
